EUDA's structural profitability remains constrained by a 27.3% gross margin, which has failed to scale sufficiently to offset the -37.0% operating margin reported in 2025Q2.
| Sales/Revenue | 5.16M | 6.82M | 4.01M | 3.71M | 3.76M | 4.56M | 8.88M |
| Revenue Growth % | 30.08% | 70.04% | 8.22% | -1.54% | -17.42% | -48.64% | - |
| Cost of Goods Sold | 4M | 3.83M | 3.25M | 2.86M | 2.89M | 3.31M | 4.99M |
| COGS % of Revenue | - | 56.12% | 81% | 77.28% | 76.89% | 72.58% | 56.17% |
| Gross Profit | 1.16M | 2.99M | 762.15K | 842.08K | 870K | 1.25M | 3.89M |
| Gross Margin % | 22.39% | 43.88% | 19% | 22.72% | 23.11% | 27.42% | 43.83% |
| Gross Profit Growth % | - | 292.68% | -9.49% | -3.21% | -30.4% | -67.87% | - |
| Operating Expenses | 3.28M | 5.43M | 18.1M | 4.8M | 13.09M | 1.81M | 4.78M |
| OpEx % of Revenue | - | 79.66% | 451.19% | 129.59% | 347.72% | 39.71% | 53.9% |
| Selling, General & Admin | 3.28M | 5.43M | 3.34M | 4.8M | 6.75M | 1.81M | 4.63M |
| SG&A % of Revenue | - | 79.66% | 83.32% | 129.59% | 179.33% | 39.71% | 52.12% |
| Research & Development | 244 | 249 | 0 | 0 | 17.21K | 129.26K | 158.01K |
| R&D % of Revenue | - | 0% | - | - | 0.46% | 2.84% | 1.78% |
| Other Operating Expenses | 0 | 0 | 14.76M | 0 | 6.32M | -129.26K | 0 |
| Operating Income | -2.12M | -2.44M | -17.34M | -3.96M | -5.72M | -559.99K | -893.56K |
| Operating Margin % | -41.13% | -35.78% | -432.19% | -106.87% | -151.93% | -12.28% | -10.07% |
| Operating Income Growth % | - | 85.92% | -337.64% | 30.74% | -921.29% | 37.33% | - |
| EBITDA | -1.99M | -2.03M | -17.16M | -3.85M | -5.46M | -295.89K | -669.44K |
| EBITDA Margin % | -38.61% | -29.82% | -427.87% | -103.87% | -145.12% | -6.49% | -7.54% |
| EBITDA Growth % | 91.35% | 88.15% | -345.78% | 29.53% | -1746.25% | 55.8% | - |
| D&A (Non-Cash Add-back) | 129.76K | 406.48K | 173.22K | 111.2K | 256.26K | 264.1K | 224.12K |
| EBIT | -2.12M | -2.5M | -17.6M | -8.41M | -24.81M | 1.08M | -893.56K |
| Net Interest Income | -45.59K | -228.62K | -44.89K | -23.23K | -93.78K | 1.79M | -65.82K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 1.92M | 0 |
| Interest Expense | 45.59K | 228.62K | 44.89K | 23.23K | 93.78K | 127.13K | 65.82K |
| Other Income/Expense | 23.41K | -285.26K | -307.38K | -4.47M | -19.21M | 2.23M | 1.14M |
| Pretax Income | -2.1M | -2.73M | -17.64M | -8.43M | -24.93M | 1.67M | 246.45K |
| Pretax Margin % | -40.67% | -39.97% | -439.85% | -227.57% | -662.32% | 36.62% | 2.78% |
| Income Tax | 7.67K | 41.94K | -4.38K | 0 | -20.79K | 46.49K | 47.48K |
| Effective Tax Rate % | -0.37% | -1.54% | 0.02% | 0% | 0.08% | 2.78% | 19.26% |
| Net Income | 266.67K | -2.77M | -15.36M | -10.04M | -24.88M | 864.83K | 175.57K |
| Net Margin % | 5.17% | -40.65% | -382.87% | -270.86% | -661.06% | 18.97% | 1.98% |
| Net Income Growth % | 101.13% | 81.94% | -52.97% | 59.66% | -2977.35% | 392.57% | - |
| Net Income (Continuing) | -2.11M | -2.77M | -17.64M | -8.43M | -25.01M | 1.62M | 198.97K |
| Discontinued Operations | 2M | 0 | 2.25M | -1.6M | 58.66K | -722.44K | 0 |
| Minority Interest | -16.75K | -12.58K | -19.01K | 16.61K | 13.48K | 78.82K | 43.23K |
| EPS (Diluted) | 0.14 | -1.49 | -9.40 | -8.80 | -41.40 | 1.87 | 0.47 |
| EPS Growth % | 93.79% | 84.15% | -6.82% | 78.74% | -2313.9% | 294.51% | - |
| EPS (Basic) | - | -1.49 | -9.40 | -7.40 | -41.40 | 1.87 | 0.47 |
| Diluted Shares Outstanding | 1.86M | 1.86M | 1.62M | 1.15M | 601.48K | 462.67K | 371.11K |
| Basic Shares Outstanding | 1.86M | 1.86M | 1.62M | 1.36M | 601.48K | 462.67K | 371.11K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
According to the provided financial data, EUDA's revenue trajectory remains highly volatile, with recent quarterly growth of 60.2% masking significant historical fluctuations that suggest the company has yet to establish a predictable, scalable top-line expansion model within the competitive Singaporean digital health landscape.
The erratic nature of revenue growth, swinging between double-digit gains and significant contractions, indicates that the business model may be overly reliant on sporadic corporate contract wins rather than a steady, recurring subscription base. Investors should monitor whether the current growth rate is sustainable or merely a reflection of lumpy, project-based service delivery that lacks long-term durability.
As reported in financial statements, EUDA's gross margin has fluctuated around the 27% level in recent periods, which appears to be a structural limitation inherent in its service-heavy delivery model rather than a temporary operational inefficiency that can be easily resolved through scale.
The inability to consistently push gross margins above the 30% threshold suggests that the company is burdened by high variable costs, likely tied to medical practitioner payouts and pharmaceutical fulfillment. This margin profile implies that EUDA functions more like a traditional healthcare provider than a high-margin software platform, limiting its potential for operating leverage.
Based on the company's reported figures, EUDA continues to struggle with significant operating losses, as evidenced by a -37.0% operating margin in the most recent quarter, indicating that the firm has failed to achieve the necessary scale to cover its fixed overhead costs.
The persistent gap between gross profit and operating income suggests that SG&A expenses remain disproportionately high relative to the company's current revenue base. This lack of operating leverage warrants further investigation into whether management can effectively control administrative spending or if the current cost structure is fundamentally misaligned with the firm's revenue-generating capacity.
Financial data reveals a precarious cash position of only $345,145, which, when contrasted with ongoing quarterly operating losses, suggests that the company faces an acute risk of insolvency or the necessity for highly dilutive capital raises in the immediate future.
Short-sellers would likely focus on the disconnect between the company's growth narrative and its rapidly depleting cash reserves. The absence of a clear path to positive cash flow, combined with such a thin liquidity cushion, implies that the firm's survival may be contingent on external financing rather than internal operational success.
Quick answers to the most common questions about buying EUDA stock.
For fiscal year 2025, EUDA Health Holdings Limited (EUDA) reported total revenue of $6.8M. This represents a 23.2% decline compared to $8.9M in 2020.
EUDA Health Holdings Limited (EUDA) reported a net loss of $2.8M for the fiscal year ending 2025.
EUDA Health Holdings Limited (EUDA) reported an operating income of $-2.4M, resulting in an operating profit margin of -35.8%. This margin reflects the operational efficiency of the business before interest and taxes.
EUDA Health Holdings Limited (EUDA) generated $3.0M in gross profit for the year, representing a gross profit margin of 43.9%. This demonstrates the company's core pricing power and production efficiency.